Patients with acute myeloid leukemia, acute lymphocytic leukemia and myelodysplastic syndromes types of a rare blood cancers have begun receiving treatment with an investigational cell therapy across multiple cancer centers as part of a phase 3 clinical trial.

The study, known as Precision-T, is being conducted to assess the safety and efficacy differences between standard of care allogeneic hematopoietic stem cell transplant and Orca-T, a novel cell therapy.

Of note, an allogeneic hematopoietic stem cell transplant is a procedure in which a patient receives healthy stem cells from a related or unrelated donor to replace their damaged stem cells that have been affected by radiation or high doses of chemotherapy.

Orca-T is classified by its manufacturer, Orca Bio, as a high-precision cell therapy that combines purified cells from a matched donor. The investigational cell therapy is designed to not only replace a patients diseased blood and immune system with healthy cells, but also to reduce the risk for developing life-threatening transplant-related side effects such as graft versus host disease.

In graft versus host disease, the bone marrow or stem cells that have been transplanted into the patient with cancer views the recipients body as foreign. As a result of this, the donated cells or bone marrow begin to attack the recipient.

By precision engineering the donor graft, we aim to create a cell therapy that retains the benefits of transplant without serious complications like graft versus host disease and disease relapse, Dr. Robert Negrin, professor of medicine at the Stanford School of Medicine in California, said in a press release. This has been demonstrated by the recent results of the phase 1b/2 single-arm trials with Orca-T, and we are pleased to be evaluating this novel cell therapy in a randomized phase 3 clinical trial.

Orca Bio noted that it is expected that approximately 174 patients across more than 20 cancer centers including City of Hope in California as well as the Winship Cancer Institute of Emory University in Atlanta.

The main goal of the phase 3 trial is to identify the rate of moderate-to-severe chronic graft versus host disease-free survival among patients who receive Orca-T compared with those who receive standard of care allogeneic hematopoietic stem cell transplant. The investigators have defined moderate-to-severe chronic graft versus host disease-free survival as being death by any cause of moderate-to-severe chronic versus graft host disease.

Additionally, the study authors aim to assess each treatments effect on relapse-free survival (survival free of death from disease relapse) as well as graft vs. host disease and relapse-free survival, which is being defined as survival free of death from any cause, relapse, serious or severe acute graft versus host disease and moderate to severe chronic graft versus host disease.

For more news on cancer updates, research and education, dont forget tosubscribe to CUREs newsletters here.

Read the original here:
Trial to Compare Safety and Efficacy of Novel Cell Therapy to Standard of Care in Patients With Rare Blood Cancers - Curetoday.com

Medpoint Global was awarded The Best Revolutionary Hair Transplant Center of the Year. The clinic now follows developments in its field and offers more up-to-date and safer services to its patients.

California Medpoint Global, which gladly welcomes its guests from many parts of the world for hair transplant and cosmetic operations in Turkey / Istanbul, one of the leading countries in hair transplantation, has experienced an ever-increasing success rate since the day of its foundation. Medpoint Global was awarded The Best Revolutionary Hair Transplant Center of the Year. The clinic received an award from the International City Awards for its work. The clinic now follows developments in its field and offers more up-to-date and safer services to its patients.

Both men and women frequently struggle with hair loss. There are numerous potential causes; some are temporary, while others, if untreated, could lead to permanent hair loss, said the Spokesperson of Medpoint Global, At Global, we provide a variety of advanced hair treatment solutions rather than just one. To guarantee that our efforts produce pleasing results, we are committed to using top-notch technologies and advances like Otolog Plus treatment with Stem Cells. These changes have led to outcomes that are intended to bring you back to the glory days of your thick hair. That, without a doubt, improves ones appearance and boosts confidence.

Modern hair loss treatments can be found at Medpoint Global, one of Turkeys most renowned hair treatment facilities. They enhance the hairline and implant hairs in thinning places using cutting-edge techniques like the Otolog Plus Stem Cell Treatment, which helps to achieve long-lasting results that look more natural. They provide a wide range of services, including Hair transplant for men and women, Beard treatments, Eyebrow treatments, Unshaven Hair Transplants,

By combining different treatment procedures with current technology, Medpoint Global can have more effective results in less time using Otolog Plus Stem Cell Treatment, a technique created by combining otology plus stem cell therapy and steam infusion. Its purpose is to maximize nutritional quality while ensuring the repair of damaged tissues.

Stem cells, which are involved in the formation of all structures in the body, are actively used in the treatment of many diseases. Stem cells taken from the same person are given back after Medpoint Globals procedures are done. The injected cells take the form of the structure of the damaged tissues and carry out the repair of the damaged tissues.

The Otolog Plus treatment with stem cells has also been successfully applied to people with hair problems in recent years. Samples taken from the back of the neck, where the hair follicles are strongest, called the donor area, which is coded not to fall out from birth, are reproduced through a series of processes. The samples taken are made into a complete solution and injected into the areas with hair loss problems. This technique is considered a revolutionary one used by the team of experts at Medpoint Global for the best hair treatment results.

About Medpoint Global

Medpoint Global, which gladly welcomes its guests from many parts of the world for hair transplant and cosmetic operations in Turkey / Istanbul, one of the leading countries in hair transplantation, has experienced an ever-increasing success rate since the day of its foundation. Medpoint Global, which was awarded The Best Revolutionary Hair Transplant Center of the Year at the International City Awards for its work, closely follows developments in its field and offers more up-to-date and safer services to its patients. Their services include Hair transplants and treatments, beard treatments, Eyebrow treatments, Unshaven Hair Transplants and Treatments, and more.

Media ContactCompany Name: Medpoint Global Email: Send EmailCountry: TurkeyWebsite: https://medpointglobal.com/en/all-about-the-otolog-plus-stem-cell-treatment/

Go here to see the original:
Medpoint Global was awarded the Best Revolutionary Hair Transplant Center of the Year and continues to follow developments in its field and offer more...

Redding, California, Aug. 01, 2022 (GLOBE NEWSWIRE) -- According to a new market research report, Cell Culture Media Market by Product (Serum-free, Chemically Defined, Classical, Xeno-free/Animal Component Free), Application (Monoclonal Antibody, Diagnostics, Cancer and Stem Cell Research), End User (Pharma & Biotech, Academic)- Forecast to 2029, published by Meticulous Research, the cell culture media market is expected to grow at a CAGR of 13.2% from 20222029 to reach $14.64 billion by 2029.

DownloadFree Sample Report Now @https://www.meticulousresearch.com/download-sample-report/cp_id=5318

Cell culture media, also known as growth media, isany gel or liquid created to support cellular growth in an artificial environment. When scientists remove cells, organs, or tissues from living creatures, they must keep them in an appropriate artificial environment. Cell culture media contains compounds required to support and regulate the growth of cells. These cells are used in the production of biopharmaceuticals or for research purposes. Growing demand for monoclonal bodies, rising funding for cell-based research, and increased R&D spending in the life science sector are some factors driving the cell culture media market.

COVID-19 Pandemic Impact: Cell Culture Media Market

During the pandemic, major pharmaceutical and biotech companies collaborated to find vaccines and treatment methods for containing the virus. The idea behind the collaboration was to come together and find a solution as quickly as possible during the pandemic. Collaborations also took place between companies and universities to speed up the research & production process. Outsourcing pharmaceutical and biotechnological research to contract research organizations (CROs) also increased during the pandemic. Below are some of the instances,

Speak to our Analysts to Understand the Impact of COVID-19 on Your Business:https://www.meticulousresearch.com/speak-to-analyst/cp_id=5318

The global cell culture media market is segmented based on product (serum-free media, chemically defined media, classical media, animal component-free media, and other cell culture media), application [bioproduction (monoclonal antibody production, therapeutic protein production, vaccine production, and cell & gene therapy)], diagnostics, cancer research, drug screening & development, and stem cell research), end user (pharmaceutical & biotechnology companies, academic & research institutes, and diagnostic laboratories) and geography. The study also evaluates industry competitors and analyzes the regional and country markets.

On the basis of product, in 2022, the serum-free media segment is estimated to account for the largest share of the cell culture media market. The major contributing factor for the large share of this segment is the higher use of cell culture techniques in companies and research institutes, which demand media to grow cells. Some of the major benefits offered by this media include reduced risk of serum borne agents and increase in cell culture productivity. Several serum-free media have been developed and are generally formulated to support the culture of a single cell type. The segment is also expected to grow at the highest CAGR during the forecast period.

On the basis of application, the bioproduction segment is expected to grow at the highest CAGR during the forecast period. The increased production of biotherapeutics for treating diseases like cancer, diabetes, rheumatoid arthritis, and other non-communicable diseases has created an unprecedented demand for cell culture media, which, in turn, is expected to drive the growth of this segment in the forecast period.

Based on the end user, the pharmaceutical & biotechnology companies segment is expected to grow at the highest CAGR during the forecast period. The major contributing factor is the increasing demand for antibody therapeutics and emerging biosimilars in the coming years.

Quick Buy Cell Culture Media Market Research Report: https://www.meticulousresearch.com/Checkout/87099746

Geographically, North America is estimated to dominate the overall cell culture media market in 2022, followed by Europe and Asia-Pacific. Increased demand for cell-based diagnosis and treatments, the presence of major players, the availability of skilled professionals, and the presence of major research institutes are major contributing factors to the regional market's large share. However, Asia Pacific is expected to grow at the highest CAGR during the forecast period. The growth is attributed to the rising technological advancements in biotechnology & pharmaceutical centers, growing focus on developing vaccines & clinical research activities, the presence of major research organizations, low manufacturing & labor costs, and developing healthcare infrastructure.

The report also includes an extensive assessment of the product portfolio, geographic analysis, and key strategic developments adopted by leading market participants in the industry during 20192022. In recent years, the cell culture media market has witnessed several new product launches, partnerships, agreements and collaborations, expansions, and acquisitions. For instance, in January 2022, Cytiva (U.S.) signed an agreement with Nucleus Biologics, LLC (U.S.) to develop custom cell media for cell and gene therapies. Also, in November 2021, Sartorius AG (Germany) opened its Cell Culture Technology Center in Germany.

Some of the key players operating in this market are Merck KGaA (Germany), Thermo Fisher Scientific Inc. (U.S.), PromoCell GmbH (Germany), Cytiva (U.S.), Lonza Group Ltd (Switzerland), Corning Incorporated (U.S.), Becton, Dickinson and Company (U.S.), HiMedia Laboratories (India), Sartorius AG (Germany), FUJIFILM Holdings Corporation (Japan), Agilent Technologies, Inc. (U.S.), Miltenyi Biotec B.V. & Co. KG (Germany), BIOLOGOS (U.S.), STEMCELL Technologies Inc. (Canada), and Cell Applications, Inc. (U.S.).To gain more insights into the market with a detailed table of content and figures, click here:https://www.meticulousresearch.com/product/cell-culture-media-market-5318

Scope of the Report:

Cell Culture Media Market, by Product

Cell Culture Media Market, by Application

Cell Culture Media Market, by End User

Cell Culture Media Market, by Geography

DownloadFree Sample Report Now @https://www.meticulousresearch.com/download-sample-report/cp_id=5318

Related Reports:

Cell Culture Market by Product [Consumables (Media, Reagents, Sera, Cell Lines), Equipment (Bioreactor, Centrifuge, Cell Counter)], Application (Bioproduction, Cancer Research, Stem Cell, Diagnostic), End User (Pharma, Academic)Global Forecast to 2029

https://www.meticulousresearch.com/product/cell-culture-market-4788

In-Vitro Toxicology/Toxicity Testing Market by Product and Service, Technology (Cell Culture, OMICS), Method (Cell-based Assays, In-Silico), End-point (ADME, Genotoxicity, Organ Toxicity, Dermal Toxicity), End-user, and Geography - Global Forecast to 2025

https://www.meticulousresearch.com/product/in-vitro-toxicology-toxicity-testing-market-5047

Cell Isolation/Cell Separation Market by Product (Reagents, Beads, Media, Disposables, Centrifuge, Filtration System), Cell Type (Human, Animal), Technology (Filtration, Surface Marker), Application (Research, Therapeutics), End User- Global Forecast to 2024

https://www.meticulousresearch.com/product/Cell-Isolation-Cell-Separation-Market-4966

About Meticulous Research

Meticulous Research was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze, and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.

Contact:Mr.Khushal BombeMeticulous Market Research Inc.1267WillisSt,Ste200 Redding,California,96001, U.S.USA: +1-646-781-8004Europe : +44-203-868-8738APAC: +91 744-7780008Email-sales@meticulousresearch.comVisit Our Website:https://www.meticulousresearch.com/Connect with us on LinkedIn-https://www.linkedin.com/company/meticulous-researchContent Source: https://www.meticulousresearch.com/pressrelease/542/cell-culture-media-market-2029

Read the rest here:
Cell Culture Media Market Worth $14.64 Billion by 2029 - Exclusive Report by Meticulous Research - GlobeNewswire